Investment Rating - The report maintains a "Recommended" rating for the company [5][7]. Core Insights - The company has signed an agreement with Pfizer to exclusively grant rights for its innovative PD-1/VEGF bispecific antibody SSGJ-707, receiving an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [3][4]. - SSGJ-707 shows best-in-class potential with promising clinical data in treating non-small cell lung cancer (NSCLC) and has received breakthrough therapy designation from the National Medical Products Administration [4]. - The company has a robust pipeline with 30 products in development, several of which are nearing market application, indicating a fruitful period ahead for its innovation pipeline [4]. Financial Projections - The company expects total revenue of RMB 182.44 billion, RMB 127.52 billion, and RMB 147.31 billion for the years 2025, 2026, and 2027 respectively, with corresponding net profits of RMB 85.75 billion, RMB 34.13 billion, and RMB 41.02 billion [5][6]. - Earnings per share (EPS) are projected to be RMB 3.57, RMB 1.42, and RMB 1.71 for the years 2025, 2026, and 2027 respectively [6][9]. Business Development - The company is expanding its commercial footprint through partnerships, having secured four collaborations in 2024, which will enhance its product portfolio and revenue growth [5][4]. - Core products are expected to continue stable growth in 2024, with ongoing expansion into new indications and formulations [5].

Investment Rating - The report maintains a "Recommended" rating for the company [5][7]. Core Insights - The company has signed an agreement with Pfizer to exclusively grant rights for its innovative PD-1/VEGF bispecific antibody SSGJ-707, receiving an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [3][4]. - SSGJ-707 shows best-in-class potential with promising clinical data in non-small cell lung cancer (NSCLC), having received breakthrough therapy designation from the National Medical Products Administration [4]. - The company has a robust pipeline with 30 products in development, several of which are nearing market application, indicating a fruitful period ahead for innovation [4]. Financial Projections - The company expects total revenue of RMB 182.44 billion, RMB 127.52 billion, and RMB 147.31 billion for the years 2025, 2026, and 2027 respectively, with corresponding net profits of RMB 85.75 billion, RMB 34.13 billion, and RMB 41.02 billion [5][6]. - Earnings per share (EPS) are projected to be RMB 3.57, RMB 1.42, and RMB 1.71 for the years 2025, 2026, and 2027 respectively [6][9]. Business Development - The company is expanding its commercial footprint through collaborations, having secured four partnerships in 2024, which will enhance its product portfolio and revenue growth [5][4]. - Core products are expected to continue stable growth in 2024, with ongoing expansion into new indications and formulations [5].